ǰÑÔ
ÁܰÍÁö(lymphoma)ÊDZ¬·¢ÓÚÁÜͶºÏ¼°£¨»ò£©ÁÜͶºÏÍâÁܰÍ×éÖ¯µÄ¶ñÐÔÖ×Áö£¬ÊÇÒ»Àà°üÀ¨¶àÖÖ²î±ðÁÙ´²ÌåÏֺͷÖ×ÓÉúÎïÑ§ÌØÕ÷µÄÖ×Áö¡£½üÄêÀ´£¬Ëæ×۬×̲¡¼°¼Ì·¢ÐÔÃâÒßÒÖÖÆ¼²²¡µÄÔö¶à£¬Æä·¢²¡ÂÊÔÚÌìϸ÷¹úÏÔ×ÅÉÏÉý£¬µ«Æä»ù´¡ºÍÁÙ´²Ñо¿Éî¶ÈºÍ¹ã¶ÈÈÔºÜÓÐÏÞ¡£½üÄêÀ´£¬ÈËÃÇÏà¼Ì½¨ÉèÖÖÖÖÁܰÍÁö¶¯ÎïÄ£×Ó£¬´Ó×Ô¾õÐÔ¡¢ÓÕ·¢ÐÔÖ×ÁöÄ£×Óµ½ÆÕ±éÔËÓõÄÒÆÖ²ÐÔÖ×ÁöÄ£×ÓÒÔ¼°ÔËÓ÷Ö×ÓÉúÎïѧÊÖÒÕ½¨ÉèµÄת»ùÒò¶¯ÎïÄ£×ӵȣ¬ÕâЩģ×ÓΪÉîÈëÑо¿ÁܰÍÁö²¡Òò¡¢·¢²¡»úÖÆ¡¢Õï¶ÏºÍÖÎÁƵÈÌṩÁËÓÐÓõÄÑо¿ÊֶΡ£
²¿·ÖÔìÄ£ÒªÁì
ʹÓö¯ÎСÊó
¡¾ÔìÄ£»úÖÆ¡¿£º
ÁܰÍÁöµÄ±¬·¢ÊÇÒ»¸ö¶àÒòËØ¼ÓÈë¼°¶à½×¶ÎµÄÀú³Ì¡£Ï¸°ûÖÜÆÚµ÷¿Ø¡¢¿¹µòÍöͨ·¼°Ö×ÁöÒÖÖÆÍ¨Â·Òì³£µÈ¶àÖÖ»úÖÆÔÚÁܰÍÁöµÄ·¢²¡ÖÐÆðÖ÷Òª×÷Óá£Ê¹ÓÃÍâÔ´ÐÔÒªÁ죬°Ñ·Ö×ÓˮƽºÍÕûÌåˮƽÍŽáÆðÀ´£¬ÔÚ»îÌåÖп¿½üÕæÊµµØÔÙÏÖÄ³Ò»ÌØ¶¨»ùÒòµÄ±í´ïºÍËùµ¼ÖµÄЧ¹û£¬½¨ÉèÌØ¶¨µÄת»ùÒò¶¯ÎïÄ£×ÓÊÇÏÖÔÚÌõÀí×î¸ßµÄʵÑéϵͳ¡£
¡¾ÔìÄ£ÒªÁì¡¿£º
1985Ä꣬AdamsµÈÊ״ι¹½¨ÁËmyc°©»ùÒòÖб¬·¢ÁËÒ×λµÄBϸ°ûÁܰÍÁöת»ùÒòСÊóÄ£×Ó£¬È¥µ÷¿ØÐòÁеÄmyc»ùÒòתÈëºó×Ô¼ºÎÞÉúÎïѧ»îÐÔ£¬½ÓÉÏlgÖØÁ´5c¶ËÔöÇ¿×Ó(Em)ºó£¬ÀàËÆÓÚBurkittÁܰÍÁö»¼Õß8ºÅȾɫÌåÉÏc-mycÔ°©»ùÒòºÍ14ºÅȾɫÌå¡¢2ºÅȾɫÌå»ò22ºÅȾɫÌåÉÏlgÖØÁ´»òÇáÁ´»ùÒòµÄÒ×λ£¬Ã¿Ö»×ª»ùÒòÊó³öÉúºó¼¸¸öÔÂÄÚ¾ùÉú³¤ÎªBϸ°ûÁܰÍÁö£¬½øÒ»²½Ö¤ÊµÁËȾɫÌåÒ×λµ¼ÖÂc-myc¸ß±í´ïÊÇBurkittÁܰÍÁö±¬·¢µÄÖ÷ÒªÔµ¹ÊÔÓÉ¡£ÔÙÕߣ¬t(2;5) (q23;q35)Ò×λÊǼä±äÐÔ´óϸ°ûÁܰÍÁö(ALCL)ÖÐ×î³£¼ûµÄºËÐÍÒì³££¬t(2;5)ʹNPM/B23»ùÒòN¶Ë½á¹¹ÓòÓëALK»ùÒòÐγÉÈںϻùÒòNPM/ALK£¬ÓÕµ¼ÈÚºÏÂѰ×NPM/ALK£¨»òP80)±í´ï£¬Ôö½øALCLµÄ±¬·¢¡£NPM-ALKת»ùÒòÊó¶¯ÎïÄ£×ӵĽ¨ÉèΪ²ûÊÍALK½éµ¼µÄϸ°û¶ñÐÔת»¯µÄ·Ö×Ó»úÖÆÌṩÁ˼áʵµÄ»ù´¡£¬Í¬Ê±½øÒ»²½Ö§³ÖÁËÈںϻùÒòNPM-ALKµÄ°©»ùÒòÌØÕ÷¡£ÉÐÓлùÒòÇÃÈëÄ£×Ó¡£ÈçNSHP-2D61G»òÕßSHP-2E76K»ùÒòÇÃÈëСÊ󣬾ù±¬·¢ÁܰÍÁö¡£
¡¾Ä£×ÓÌØµã¡¿£º
ת»ùÒò¶¯ÎïÄ£×ÓÒ²ÓÃÓÚÁܰÍÁöÒÖÖÆÑо¿£¬¿Éͨ¹ý²î±ðת»ùÒò¶¯Îï¼äµÄÔÓ½»ÐγɵĶà»ùÒòת»ùÒò¶¯Î½èÒÔÑо¿²î±ð»ùÒòÔÚÁܰÍÁö±¬·¢Éú³¤Àú³ÌÖеÄÐͬ×÷Óá£SHP-2D61G»òSHP- 2E76KСÊó£¬ÔÚ400~600radµ¥´Î·øÕպ󣬴󲿷ֱ¬·¢ÁܰÍÁö»òÕßTϸ°û°×Ѫ²¡¡£
¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º
ת»ùÒòµÄÒªÁìÏÖÔÚÓÐÐí¶àÖÖ£¬ÓÃÓÚ¸´Öƶ¯ÎïÄ£×Ó£¬¿ÉÒÔ´Ó·Ö×ÓˮƽÑо¿ÁܰÍÁöµÄ²¡Òò£¬¿ÉÑо¿ÁܰÍÁö±¬·¢Ïà¹Ø»ùÒòµÄ¹¦Ð§¼°ÐźÅתµ¼Í¾¾¶£¬Ò²¿ÉÓÃÓÚɸѡ¿¹°©Ò©Î¿ª·¢ÁËÁܰÍÁö½¨Ä£µÄÕ¸ÐÂ;¾¶£¬µ«ÈÔÓÐÒ»¶¨µÄȱÏÝ£¬Èç»ùÒò¿½±´ÊýµÄ²»¿É¿ØÐÔ¼°ÕûºÏλµãµÄËæ»úÐԵȣ¬±íÐÍÆÊÎöÒ²±£´æÒ»¶¨ÄѶȣ¬µ«¾ÍÏÖÔÚÀ´Ëµ£¬×ª»ùÒòÊÖÒÕÈÔÊÇÑо¿Ö×Áö±¬·¢¡¢Éú³¤¡¢×ªÒƵÄÓÐÓÃÊÖÒÕ¡£SHP- 2D61GСÊó·øÕÕºóÓе䷶µÄÐØÏÙÔö´ó¡¢ÁÜͶºÏµÈÁܰÍÁö±íÐÍ¡£
²Î¿¼ÎÄÏ×£º
1.ÓÚÀ×£¬ÁõÓÀÕÜ£¬ËïÊÀÁú£¬µÈ£®c-myc»ùÒòÓë·øÉäÓÕ·¢Ð¡ÊóÐØÏÙÁܰÍÁöµÄ¹ØÁªÐÔÆÊÎö£®¼ªÁÖ´óѧѧ±¨£¨Ò½Ñ§°æ£©£¬2009, 35 (6):971-974
2.ÒüÖ¾»ª£¬ÌÚ·É£¬ÌÆÔËÁ«£¬µÈ£®»·æßËØA¶ÔÎȹÌEBVÓÕ·¢ÁܰÍÁöÄ£×ÓµÄ×÷ÓúÍÒâÒ壮ÖйúÃâÒßѧÔÓÖ¾£¬2002, 18(11):760-763
3.ÇñÑǾ꣬ÕÅÃ÷ÖÇ£¬ÀîÁᣮEB²¡¶¾ÓëÁܰÍÁö£®¹ú¼ÊÖ×ÁöѧÔÓÖ¾£¬2011, 38 (5):387-389
4.»Æ¸ñ·¼£¬ÓàÓ¢ºÀ£¬À£®N£¼×»ùÑÇÏõ»ùëåÓÕµ¼Ð¡ÊóÐØÏÙÁܰÍÁöTCR»ùÒòÖØÅÅÆÊÎö£®Öйú½ÏÁ¿Ò½Ñ§ÔÓÖ¾£¬2010,20(9):7-11
5.Xu D,Wang S,Yu WM,et al. A germline gain-of function mutation in Ptpnl 1 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. Blood,2010, 116(18):3611- 3621
6.Chen HJ.Yang BL,Chen YG,et al. A GFP-labeled human colon cancer metastasis model featuring surgical orthotopic implantation. Asian Pac J Cancer Prev, 2012, 13 (9):4263-4266
7.Chiarle R,Gong JZ,Guasparri¢ñ,et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood, 2003, 101 (5):1919-1927
8.Wang S, Yu WM, Zhang W, et al. Noonan syndrome/ leukemia-associated gain-of-function mutations in SHP-2 phosphatase (PTPN 11) enhance cell migration and angiogenesis. J Biol Chem,2009,284(2):913-920
9.Benavides F, Gomez G, Venables-Griffith A, et al.Differential susceptibility to chemically induced thymic lymphomas in SENGARB and SSIN inbred mice. Mol Carcinog,2006,45 (7):543-548
10.da Silva Franchi CA,Bacchi MM,et al. Thymic lymphomas in Wistar rats exposed to N-methyl-N nitrosourea (MNU). Cancer Sci,2003,94(3):240-243